- Home
- RAPT
as 12-18-2024 12:41pm EST
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 30.8M | IPO Year: | 2019 |
| Target Price: | $5.00 | AVG Volume (30 days): | 394.7K |
| Analyst Decision: | Hold | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.78 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.84 - $27.35 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest RAPT Therapeutics Inc. News
RAPT Breaking Stock News: Dive into RAPT Ticker-Specific Updates for Smart Investing
MT Newswires
a month ago
Stifel Nicolaus Downgrades RAPT Therapeutics to Hold From Buy, Cuts Price Target to $2 From $7
GlobeNewswire
a month ago
RAPT Therapeutics Reports Third Quarter 2024 Financial Results
MT Newswires
a month ago
Top Midday Decliners
MT Newswires
a month ago
JPMorgan Downgrades RAPT Therapeutics to Underweight From Neutral; Shares Plunge
Clinical Trials Arena
a month ago
RAPT Therapeutics shares tumble by 48% after zelnecirnon programme cull
MT Newswires
a month ago
RAPT Therapeutics Ends Zelnecirnon Program After FDA Hold on Trials
GlobeNewswire
a month ago
Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury
Simply Wall St.
a month ago
Companies Like RAPT Therapeutics (NASDAQ:RAPT) Could Be Quite Risky
Compare RAPT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RAPT RAPT Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.